144 related articles for article (PubMed ID: 38638426)
1. A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a "βγ-only" interleukin-2 variant.
Jiang Y; Chen C; Liu Y; Wang R; Feng C; Cai L; Chang S; Zhao L
Front Immunol; 2024; 15():1369376. PubMed ID: 38638426
[TBL] [Abstract][Full Text] [Related]
2. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract][Full Text] [Related]
4. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1.
Ramaswamy M; Kim T; Jones DC; Ghadially H; Mahmoud TI; Garcia A; Browne G; Zenonos Z; Puplampu-Dove Y; Riggs JM; Bhat GK; Herbst R; Schofield DJ; Carlesso G
Cancer Immunol Res; 2022 Feb; 10(2):200-214. PubMed ID: 34937728
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
7. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
9. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
10. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
11. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
12. The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD
Siebert N; Leopold J; Zumpe M; Troschke-Meurer S; Biskupski S; Zikoridse A; Lode HN
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230765
[TBL] [Abstract][Full Text] [Related]
13. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4
Awad RM; De Vlaeminck Y; Meeus F; Ertveldt T; Zeven K; Ceuppens H; Goyvaerts C; Verdonck M; Salguero G; Raes G; Devoogdt N; Breckpot K
Sci Rep; 2023 Nov; 13(1):18995. PubMed ID: 37923822
[TBL] [Abstract][Full Text] [Related]
14. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
15. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
[TBL] [Abstract][Full Text] [Related]
16. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.
Li F; Li J; Yin K; Zhang J; Li ZH; Lu L; Bao YW; Qin Z; Zheng Y; Yang BT; Li J; Wang X
Acta Pharmacol Sin; 2021 Jan; 42(1):142-148. PubMed ID: 32467569
[TBL] [Abstract][Full Text] [Related]
17. The PD-1 with PD-L1 Axis Is Pertinent with the Immune Modulation of Atrial Fibrillation by Regulating T Cell Excitation and Promoting the Secretion of Inflammatory Factors.
Chang G; Chen Y; Liu Z; Wang Y; Ge W; Kang Y; Guo S
J Immunol Res; 2022; 2022():3647817. PubMed ID: 35600045
[TBL] [Abstract][Full Text] [Related]
18. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
19. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
Front Immunol; 2020; 11():832. PubMed ID: 32457754
[TBL] [Abstract][Full Text] [Related]
20. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
